ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0173

Greater High-density Lipoprotein Levels over Time Are Linked to Lower Coronary Plaque Formation, Regression and Stabilization of High-risk Lesions in Rheumatoid Arthritis

George Karpouzas1, sarah ormseth2, Elizabeth Hernandez2 and Matthew Budoff3, 1Harbor-UCLA Medical Center, Torrance, CA, 2The Lundquist Institute, Harbor-UCLA Medical Center, Torrance, CA, 3Division of Cardiology, and the Lundquist Institute ay Harbor-UCLA Medical Center, Torrance, CA

Meeting: ACR Convergence 2021

Keywords: Computed tomography (CT), coronary atherosclerosis progression, epicardial fat, rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 6, 2021

Title: Imaging of Rheumatic Diseases Poster (0149–0182)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: The relationship between serum lipoproteins and cardiovascular (CV) disease risk in rheumatoid arthritis (RA) is complex. Their levels and function may vary based on disease activity and medication use. Treatment benefits on high-density lipoprotein (HDL) levels, structure and behavior, in response to treatment have been described. Yet, the impact of HDL-C levels over time on coronary atherosclerosis progression in RA is unknown. We here evaluated the influence of HDL-C levels over time on long-term coronary plaque formation and progression in RA.

Methods: One hundred one patients without CV disease who underwent computed tomography angiography study of coronary atherosclerosis had repeat assessments after 6.9±0.3 years to evaluate plaque progression. Clinical, laboratory and medication data were captured at baseline and throughout follow-up. Robust logistic regression assessed associations between time-averaged HDL-C and likelihood of new plaque formation in segments without plaque at baseline, and transition of partially calcified to fully calcified plaque. Robust multinomial logistic regression evaluated effects of time-averaged HDL-C on likelihood of new noncalcified, partially or fully calcified plaque in segments without plaque (compared to remaining without plaque), and noncalcified plaque regression or transition to partially or fully calcified plaque (compared to remaining noncalcified). Models accounted for clustering of segments within patients and adjusted for Framingham CV risk score, segment location, time-averaged CRP, prednisone dose, bDMARD and statin duration, obesity, and time-averaged triglycerides.

Results: Participants were mostly female (n=87, 86.1%), 51.5±10.3 years old and time-averaged HDL-C was 51.7±13.9. Ninety-seven new plaques formed in segments without baseline plaque; 20 were noncalcified, 21 partially, and 56 were fully calcified. Time-averaged HDL-C had no effect on new total plaque formation (adjusted OR 0.88 [95% CI 0.64-1.21]). However, each SD increase in time-averaged HDL-C associated with a 44% lower chance of new noncalcified plaque (adjusted OR 0.56 [95% CI 0.35-0.92], Figure 1); no effect on incident partially or fully calcified plaque was observed. Of 98 noncalcified plaques at baseline, 42 remained unchanged, 32 regressed, 16 transitioned to partially and 8 to fully calcified plaques. Each SD increase in time-averaged HDL-C yielded a 2.2-fold greater chance of noncalcified plaque regression (adjusted OR 2.21 [95% CI 1.02-4.83]). Sixteen of 52 partially calcified plaques transitioned to fully calcified lesions; each SD increment in time-averaged HDL-C) predicted 3.5-fold greater odds of transition of partially to fully calcified plaque (adjusted OR 3.56 [95% CI 1.25-10.17]).

Conclusion: Higher HDL-C over time predicted regression of existing and decreased formation of new higher-risk noncalcified plaque. It also associated with transition of partially calcified to more stable fully calcified plaque. All effects were independent of RA treatment duration, prednisone dose and statin exposure.

Figure 1. Impact of HDL-C over time on coronary plaque progression in RA


Disclosures: G. Karpouzas, None; s. ormseth, None; E. Hernandez, None; M. Budoff, None.

To cite this abstract in AMA style:

Karpouzas G, ormseth s, Hernandez E, Budoff M. Greater High-density Lipoprotein Levels over Time Are Linked to Lower Coronary Plaque Formation, Regression and Stabilization of High-risk Lesions in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/greater-high-density-lipoprotein-levels-over-time-are-linked-to-lower-coronary-plaque-formation-regression-and-stabilization-of-high-risk-lesions-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/greater-high-density-lipoprotein-levels-over-time-are-linked-to-lower-coronary-plaque-formation-regression-and-stabilization-of-high-risk-lesions-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology